07:39 EDT Harmony Biosciences (HRMY) backs FY26 revenue view $1B-$1.04B, consensus $1.02B
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- H.C. Wainwright views weakness in Harmony shares as ‘excessive IP overhang’
- Harmony Biosciences price target raised to $72 from $62 at Oppenheimer
- Harmony patent litigation update ‘major positive,’ says Mizuho
- Harmony jumps 14% to $33.58 after Mizuho uncovers new patent lawsuit
- Harmony extends rally, shares up 16% after Mizuho research note